Johnson & Johnson Return on Tangible Equity 2012-2026 | JNJ
Current and historical return on tangible equity values for Johnson & Johnson (JNJ) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Unlock Macrotrends Premium
Start 7-Day Free Trial
Johnson & Johnson Return On Tangible Equity Historical Data
Date
TTM Net Income
Tangible Equity
Return on Tangible Equity
2025-12-31
$26.80B
$-14.43B
-185.71%
2025-09-30
$25.12B
$-12.61B
-199.24%
2025-06-30
$22.66B
$-11.76B
-192.65%
2025-03-31
$21.81B
$-10.00B
-218.05%
2024-12-31
$14.07B
$-9.45B
-148.93%
2024-09-30
$14.68B
$-7.35B
-199.72%
2024-06-30
$38.02B
$-3.80B
-1000.80%
2024-03-31
$38.48B
$-4.51B
-853.36%
2023-12-31
$35.15B
$-9.83B
-357.73%
2023-09-30
$34.62B
$-8.77B
-394.80%
2023-06-30
$13.05B
$-8.57B
-152.31%
2023-03-31
$12.72B
$-4.81B
-264.77%
2022-12-31
$17.94B
$-0.43B
-4184.49%
2022-09-30
$19.16B
$-2.90B
-660.70%
2022-06-30
$18.37B
$-6.39B
-287.52%
2022-03-31
$19.83B
$-10.45B
-189.68%
2021-12-31
$20.88B
$-14.53B
-143.65%
2021-09-30
$17.88B
$-19.26B
-92.84%
2021-06-30
$17.77B
$-20.20B
-87.95%
2021-03-31
$15.12B
$-20.66B
-73.16%
2020-12-31
$14.71B
$-20.30B
-72.49%
2020-09-30
$16.99B
$-19.12B
-88.83%
2020-06-30
$15.19B
$-20.65B
-73.55%
2020-03-31
$17.17B
$-21.62B
-79.42%
2019-12-31
$15.12B
$-21.59B
-70.04%
2019-09-30
$14.15B
$-20.71B
-68.33%
2019-06-30
$16.33B
$-18.66B
-87.54%
2019-03-31
$14.68B
$-17.48B
-83.96%
2018-12-31
$15.30B
$-17.70B
-86.43%
2018-09-30
$1.54B
$-19.37B
-7.96%
2018-06-30
$1.37B
$-18.66B
-7.35%
2018-03-31
$1.25B
$-17.85B
-6.98%
2017-12-31
$1.30B
$-8.77B
-14.82%
2017-09-30
$15.83B
$2.65B
596.35%
2017-06-30
$16.34B
$11.12B
146.93%
2017-03-31
$16.51B
$20.85B
79.16%
2016-12-31
$16.54B
$23.08B
71.66%
2016-09-30
$15.94B
$23.84B
66.88%
2016-06-30
$15.03B
$24.42B
61.54%
2016-03-31
$15.55B
$23.91B
65.03%
2015-12-31
$15.41B
$22.54B
68.35%
2015-09-30
$14.72B
$21.78B
67.57%
2015-06-30
$16.11B
$22.87B
70.43%
2015-03-31
$15.92B
$24.45B
65.10%
2014-12-31
$16.32B
$26.26B
62.16%
2014-09-30
$17.32B
$26.91B
64.36%
2014-06-30
$15.55B
$24.37B
63.82%
2014-03-31
$15.06B
$22.05B
68.32%
2013-12-31
$13.83B
$19.48B
71.01%
2013-09-30
$12.88B
$17.06B
75.47%
2013-06-30
$12.87B
$15.74B
81.73%
2013-03-31
$10.44B
$13.29B
78.55%
2012-12-31
$10.85B
$15.88B
68.33%
2012-09-30
$8.50B
$18.17B
46.80%
2012-06-30
$8.74B
$21.69B
40.29%
2012-03-31
$10.11B
$26.11B
38.71%
2011-12-31
$9.67B
$25.66B
37.70%
2011-09-30
$11.40B
$26.10B
43.67%
2011-06-30
$11.61B
$25.50B
45.54%
2011-03-31
$12.28B
$24.06B
51.06%
2010-12-31
$13.33B
$23.08B
57.77%
2010-09-30
$13.60B
$21.79B
62.41%
2010-06-30
$13.53B
$20.26B
66.77%
2010-03-31
$13.29B
$19.16B
69.33%
2009-12-31
$12.27B
$17.59B
69.72%
2009-09-30
$12.77B
$16.45B
77.67%
2009-06-30
$12.74B
$16.06B
79.34%
2009-03-31
$12.86B
$16.02B
80.26%
2008-12-31
$12.95B
$16.35B
79.19%
2008-09-30
$12.61B
$16.29B
77.42%
2008-06-30
$11.85B
$15.51B
76.37%
2008-03-31
$11.60B
$14.69B
78.96%
2007-12-31
$10.58B
$13.57B
77.95%
2007-09-30
$10.37B
$12.59B
82.39%
2007-06-30
$10.58B
$15.88B
66.63%
2007-03-31
$10.32B
$19.26B
53.59%
2006-12-31
$11.05B
$23.39B
47.25%
2006-09-30
$10.98B
$27.37B
40.12%
2006-06-30
$10.76B
$26.75B
40.22%
2006-03-31
$10.53B
$25.62B
41.08%
2005-12-31
$10.06B
$24.03B
41.87%
2005-09-30
$8.85B
$22.39B
39.55%
2005-06-30
$8.66B
$21.14B
40.94%
2005-03-31
$8.53B
$19.96B
42.72%
2004-12-31
$8.18B
$18.76B
43.59%
2004-09-30
$9.14B
$17.60B
51.90%
2004-06-30
$8.87B
$16.17B
54.84%
2004-03-31
$7.62B
$14.79B
51.51%
2003-12-31
$7.20B
$14.18B
50.75%
2003-09-30
$6.74B
$13.71B
49.12%
2003-06-30
$6.39B
$13.40B
47.68%
2003-03-31
$6.83B
$13.38B
51.09%
2002-12-31
$6.60B
$13.39B
49.28%
2002-09-30
$6.32B
$13.81B
45.74%
2002-06-30
$6.12B
$14.66B
41.76%
2002-03-31
$5.95B
$15.28B
38.94%
2001-12-31
$5.67B
$14.85B
38.18%
2001-09-30
$5.45B
$14.27B
38.22%
2001-06-30
$5.25B
$13.02B
40.31%
2001-03-31
$5.13B
$11.89B
43.13%
2000-12-31
$4.89B
$11.07B
44.20%
2000-09-30
$4.75B
$10.01B
47.49%
2000-06-30
$4.54B
$9.23B
49.19%
2000-03-31
$4.34B
$8.44B
51.45%
1999-12-31
$4.17B
$7.72B
53.99%
1999-09-30
$3.52B
$7.15B
49.14%
1999-06-30
$3.37B
$7.79B
43.23%
1999-03-31
$3.22B
$8.45B
38.14%
1998-12-31
$3.00B
$9.14B
32.86%
1998-09-30
$3.53B
$9.82B
35.96%
1998-06-30
$3.42B
$9.39B
36.46%
1998-03-31
$3.31B
$8.99B
36.86%
1997-12-31
$3.30B
$8.63B
38.29%
1997-09-30
$3.23B
$8.28B
38.98%
1997-06-30
$3.12B
$7.99B
39.10%
1997-03-31
$3.01B
$7.71B
38.98%
1996-12-31
$2.89B
$7.42B
38.92%
1996-09-30
$2.80B
$7.01B
39.89%
1996-06-30
$2.67B
$6.59B
40.49%
1996-03-31
$2.54B
$6.21B
40.91%
1995-12-31
$2.40B
$5.84B
41.13%
1995-09-30
$2.32B
$5.50B
42.13%
1995-06-30
$2.22B
$5.33B
41.59%
1995-03-31
$2.12B
$5.30B
39.93%
1994-12-31
$2.01B
$5.22B
38.41%
1994-09-30
$1.96B
$5.20B
37.72%
1994-06-30
$1.89B
$5.11B
37.04%
1994-03-31
$1.83B
$4.95B
36.93%
1993-12-31
$1.79B
$4.88B
36.65%
1993-09-30
$1.76B
$4.83B
36.42%
1993-06-30
$1.72B
$4.88B
35.22%
1993-03-31
$1.68B
$4.88B
34.38%
1992-12-31
$1.65B
$4.93B
33.47%
1992-09-30
$1.62B
$5.04B
32.10%
1992-06-30
$1.57B
$4.89B
32.02%
1992-03-31
$1.52B
$4.74B
32.07%
1991-12-31
$1.46B
$4.54B
32.19%
1991-09-30
$1.42B
$4.37B
32.50%
1991-06-30
$1.37B
$4.22B
32.45%
1991-03-31
$1.32B
$4.10B
32.17%
1990-12-31
$1.14B
$3.93B
29.05%
1990-09-30
$1.11B
$3.75B
29.73%
1990-06-30
$1.07B
$3.54B
30.08%
1990-03-31
$1.01B
$3.34B
30.25%
1989-12-31
$1.08B
$3.17B
34.10%
1989-09-30
$1.06B
$3.04B
35.02%
1989-06-30
$1.04B
$2.95B
35.19%
1989-03-31
$1.01B
$2.93B
34.55%
1988-12-31
$0.97B
$2.96B
32.96%
1988-09-30
$0.95B
$2.95B
32.33%
1988-06-30
$0.92B
$2.89B
31.90%
1988-03-31
$0.88B
$2.79B
31.42%
1987-12-31
$0.83B
$2.62B
31.74%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $574.358B
$94.193B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
